Lactate, once considered a waste product of glycolysis, has emerged as a critical regulator of cancer development, maintenance, and metastasis. Indeed, tumor lactate levels correlate with increased metastasis, tumor recurrence, and poor outcome. Lactate mediates cancer cell intrinsic effects on metabolism and has additional non-tumor cell autonomous effects that drive tumorigenesis. Tumor cells can metabolize lactate as an energy source and shuttle lactate to neighboring cancer cells, adjacent stroma, and vascular endothelial cells, which induces metabolic reprogramming. Lactate also plays roles in promoting tumor inflammation and in functioning as a signaling molecule that stimulates tumor angiogenesis. Here we review the mechanisms of lactate production and transport and highlight emerging evidence indicating that targeting lactate metabolism is a promising approach for cancer therapeutics.
can assemble into five different combinations (LDH1 is comprised of four LDHB subunits; LDH2 contains three LDHB and one LDHA subunit; LDH3 contains two LDHB and two LDHA subunits; LDH4 contains one LDHB and three LDHA subunits; and LDH5 contains four LDHA subunits) (Figure 2 and ref. 26) . LDHB is ubiquitously expressed, although it is the predominant isoform found in heart muscle. LDHA is the predominant isoform found in skeletal muscle and other highly glycolytic tissues. Notably, LDHA has a higher affinity for pyruvate and a higher V max for pyruvate reduction than LDHB. Given this, LDHA, and in particular the LDH5 tetramer, catabolizes pyruvate to lactate and produces NAD + , which is essential for other metabolic enzymes such as GAPDH (Figure 1 and ref. 27 ). By contrast, LDHB converts lactate to pyruvate, which allows cells to use lactate as a nutrient source for oxidative metabolism (e.g., heart tissue and neurons), and/or for gluconeogenesis (e.g., in the liver and kidney) (27) .
Figure 1
Aerobic glycolysis and glutaminolysis in cancer cells. Oncoproteins drive the expression of genes involved in glycolysis and glutaminolysis, which results in production of excess amounts of lactate. Aberrant PI3K/AKT signaling and the transcriptional oncoproteins HIF-1α and MYC regulate the transcription of GLUT, HK2, TPI, ENO, and LDHA. HIF-1α induces the transcription of PFKFB3, which favors the production of F2,6BP, an allosteric activator of PFK1. The tumor suppressor protein p53 induces the expression of TIGAR, which dephosphorylates F2,6BP, blocking activation of PFK1 and inhibiting glycolysis. HIF-1α and MYC regulate the expression and splicing of the PKM2 isoform. MYC also regulates the expression of the glutamine transporter ASCT2 and GLS. Monocarboxylic acid transporters (MCTs) export lactate and protons and are regulated by HIF-1α and MYC. AcCoA, acetyl-CoA; ASP, aspartate; ASCT2, glutamine transporter; G, glucose; G6P, glucose-6-phosphate, F6P, fructose-6-phosphate; DHAP, dihydroxyacetone phosphate; GA3P, glyceraldehyde-3-phosphate; 1,3BPG, 1,3-bisphosphoglycerate; 2PG, 2-phosphoglycerate; 3PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; MDH, malate dehydrogenase; GOT, glutamic-oxaloacetic transaminase; GLUD1, glutamate dehydrogenase.
Elevated levels of LDHA are a hallmark of many tumors, the majority of which are highly glycolytic, and high LDHA connotes poor prognosis in several human malignancies (28) (29) (30) . The association of LDHB with cancer is more complex; LDHB is silenced by promoter methylation in several cancer types but is overexpressed or amplified in others, for example in human lung adenocarcinoma with KRAS mutation and in testicular germ cell tumors (31) (32) (33) (34) (35) . Thus, the efficacy of anticancer agents that target LDHA, LDHB, or both will likely differ by cancer type and metabolic phenotype.
Genetic studies have provided proof-of-principle that targeting LDHA is an attractive strategy for cancer therapeutics. First, selective knockdown of LDHA inhibits anchorage-independent growth of several transformed cell lines (10) and the in vivo growth of transplanted breast tumors (36) . Further, FX11, a small-molecule inhibitor of LDHA, impairs the growth of human pancreatic cancer and lymphoma xenografts. Interestingly, inactivation or inhibition of LDHA leads to the production of ROS, which is exacerbated by hypoxia, which drives glycolysis (36) (37) (38) . While increases in ROS could be due to redirecting pyruvate toward oxidative metabolism, mechanistic studies of MCT1 inhibitors suggest that loss of LDHA activity may trigger elevated ROS through negative feedback effects on glycolysis and on the synthesis of the major antioxidant of the cell, glutathione (39) .
Rather than using lactate as a nutrient, cancer cells generally export lactate, which acidifies the tumor environment (40) . Interestingly, lactate efflux provokes a local inflammatory response that attracts immune cells such as macrophages, which secrete cytokines and growth factors that drive tumor cell growth and metastasis (41, 42) . Indeed, the inflammatory response is often necessary for tumor progression, and elevated numbers of inflammatory cells, such as tumor-associated macrophages, connote poor prognosis (41) . Furthermore, lactate in the tumor cell milieu impairs the adaptive immune response, disabling immune surveillance (43) (44) (45) (46) . Thus, lactate also appears to promote tumorigenesis via non-tumor cell-mediated effects on the inflammatory and immune responses.
Unexpectedly, a recent report of a mouse model of B cell lymphoma (λ-Myc transgenic mice) suggested that LDHA is dispensable for the initiation and progression of lymphoma (47) . This finding was particularly surprising given the apparent importance of lactate in maintaining the malignant state and its propensity to provoke inflammation that promotes tumor progression. The authors found that a germline mutation of Ldha, which severely diminishes LDHA activity, does not affect lymphomagenesis in this model of human Burkitt lymphoma (47) . Thus, high LDHA activity may not be required for all cancers, or tumor cell metabolism may adapt to other means of gaining energy, for example a shift to OXPHOS, in the face of strong oncogenic mutations such as MYC. These findings also suggest that the efficacy of LDHA inhibitors would be augmented if used in combination with other agents that force a reliance on glycolysis.
LDHA inhibitors as cancer therapeutics
LDHA is generally considered a safe therapeutic target in humans because an inherited 20-bp deletion in the LDHA gene, which results in the loss of LDHA protein, has only relatively mild symptoms of exertional myopathy (48, 49) . Accordingly, several LDHA inhibitors are being tested for their anticancer activity (Table 1) . Gossypol (also known as AT-101), a natural product found in cottonseed, is a nonselective inhibitor of LDH that blocks the binding of NADH, with a K i for LDHA and LDHB of 1.9 and 1.4 μM, respectively (50, 51) . This compound was initially developed as an antimalarial therapeutic, but is now being used in Phase I and Phase II clinical oncology trials (52) (53) (54) . However, gossypol also inhibits GAPDH, which is an NAD + -dependent enzyme, and thus its antitumor activity may also include the inhibition of GAPDH. In addition, FX-11, a gossypol derivative that shows selectivity for LDHA over LDHB (K i of 0.05 vs. 20 μM, respectively) (55), has antitumor activity in xenograft models and has the potential to be developed into a cancer therapeutic (37, 56) . Another compound,
Figure 2
Lactate dehydrogenase activity and tetramers. (A) LDH mediates the redox-coupled conversion between lactate and NAD + with pyruvate and NADH. (B) The functional LDH enzyme is a tetramer containing differing ratios of the LDHA and LDHB subunits. The composition of the five LDH tetramers is shown. . MCT1 is expressed in most tissues at low levels, whereas MCT4 is expressed at high levels in white skeletal muscle fibers and at lower levels in other tissues, such as testis, lung, and placenta, and in some cell types such as chondrocytes, leukocytes, and astrocytes. MCT2 and MCT3 have a more restricted expression pattern; MCT2 is primarily expressed in liver, kidney, and neurons in the brain, while MCT3 expression is restricted to basolateral retinal pigment epithelium and the choroid plexus. A notable, and exploitable, feature of MCT transporters is that cochaperone immunoglobulin-family single-membrane pass proteins are required for their transport to the surface of the cell membrane. Specifically, MCT1, MCT3, and MCT4 bind to CD147 (also known as basigin, EMMRIN, and OX-47), which is required for their expression on the cell surface, whereas MCT2 binds and requires embigin for cell surface expression (60, 61) . Notably, the expression of CD147 on the cell surface also depends on co-expression with an MCT protein, and this interaction stabilizes both binding partners (62) .
Marked increases in the levels of MCT1 and/or MCT4 are a hallmark of several human malignancies, and high levels of these transporters connote poor outcome. For example, elevated levels of MCT1 have been detected in breast, colorectal, gastric, and cervical cancer as well as in neuroblastoma and glioma (63) (64) (65) (66) (67) (68) . In contrast, MCT4 expression is highly elevated in renal cell carcinoma as well as in cervical and prostate cancer (65, 69, 70) . Importantly, the elevated expression of MCT1 and MCT4 in cancer provides a therapeutic window for disabling these transporters with smallmolecule inhibitors and/or by targeting their cochaperone CD147, for example using CD147-specific antibody therapeutics.
While essentially nothing is known regarding the control of MCT2 and MCT3 expression, several studies have shed light on the regulation of MCT1 and MCT4 expression. MCT4 is a direct transcription target of HIF-1α and is markedly upregulated in response to hypoxia (71, 72) . MCT4 is also expressed at basal levels in several tissues and cell types (e.g., astrocytes), though the mechanism(s) underlying the regulation of basal expression are not clear. MCT1 expression is normally silenced in pancreatic β cells by both histone methylation (H3K27me3) at the promoter and by miR targeting of the transcript (73, 74) . Further, MCT1 promoter methylation of CpG islands and transcriptional repression have been documented in the breast cancer cell line MDA-MB-231 (75) . Other cues also appear to regulate MCT1 expression. In muscle cells, increases in extracellular lactate that occur following high-intensity exercise induce MCT1 expression, apparently via the generation of ROS (76) , and this response may be relevant to MCT1 control in highly glycolytic, oxidative tumor cells and in adjacent stromal cells that are bathed in lactate. Furthermore, p53 represses MCT1 transcription and decreases the stability of MCT1 transcripts during hypoxia; thus, loss of p53 during tumorigenesis or the acquisition of therapeutic resistance can also augment MCT1 expression (77) . Stage IV human neuroblastomas that contain MYCN amplification express high levels of MCT1 transcripts (64), suggesting that MYC regulates MCT1 transcription. Increased levels of MCT1 in tumors expressing high levels of MYC have also been noted in expression arrays (78, 79) , and genome-wide chromatin immunoprecipitation analyses of MYC binding indicate that MYC binds to the MCT1 promoter of both normal and cancer cell lines (80). Collectively, these findings suggest that MCT1 may be a transcriptional target of MYC and that targeting MCT1 may be an attractive strategy to disable MYC-driven malignancies.
Genetic knockdown studies and the development of several small-molecule inhibitors have established the relevance of targeting lactate transporters in cancer therapeutics. Knockdown of MCT1 (and in some cases, MCT2) in glioblastoma (GBM) cells or inhibition of MCTs with the small molecule α-cyano-4-hydroxycinnamate (CHC) impairs GBM cell proliferation, migration, and survival (39, 63, 81) . Furthermore, CHC impairs tumorigenic potential of GBM in intracranial xenografts (82) . More convincingly, inhibition of MCT1 with highly selective and potent MCT1/ MCT2 inhibitors that were originally developed by AstraZeneca to block the proliferation of activated T cells (e.g., AR-C155858; refs. 83, 84) impairs the growth and tumorigenicity of Ras-transformed fibroblasts (85) . Furthermore, a second-generation MCT1/ MCT2 inhibitor (AZD3965) is currently in Phase I clinical trials for advanced solid tumors and for diffuse large B cell lymphoma (86) . However, these drugs fail to clear hypoxic regions of otherwise-MCT1-expressing tumors, due to HIF-1α-directed induction of MCT4 (85) . In addition, these agents do not bind to MCT4 and are thus ineffective against MCT4-expressing tumors and transformed cells lines. MCT4 also plays key roles in tumorigenesis, and knockdown experiments have shown that MCT4 is required for migration and invasion of MCT4-expressing tumor cells (62, 87, 88) and for the interplay of cancer cells with stromal cells in the tumor microenvironment (see below). Thus, there is a clear need to develop potent small molecules that function as pan-MCT inhibitors, or that selectively disable MCT4.
Targeting MCT chaperones for cancer therapeutics
Given its requirement for stabilizing and localizing MCTs to the cell membrane (60), targeting CD147 is also an attractive antitumor strategy. One approach involves the generation of humanized anti-CD147 antibodies that can induce antibody-dependent cell-mediated cytotoxicity (ADCC). Such antibodies might also be utilized to deliver covalently attached drug payloads to CD147/MCT-expressing tumor cells, which will kill cancer cells irrespective of their MCT expression status. Furthermore, the organomercurial reagent p-chloromercuribenzene sulfonate (pCMBS) inhibits the activity of MCT1 and MCT4 by disrupting their association with CD147 (89) . Mechanistically, this disruption occurs via pCMBS-directed reduction of the disulfide bond in the Ig-like domain of CD147. However, this agent is likely promiscuous and may target other immunoglobulin family proteins. Proof-of-principle that targeting CD147 is an attractive approach has been established by knockdown studies and by using anti-CD147 antibodies, which showed that, as expected, loss of CD147 function markedly reduces the levels of MCT1 and MCT4 proteins and impairs the growth of tumor xenografts (85, 90, 91) . However, on a cautionary note, CD147 is ubiquitously expressed and interacts with other proteins at the cell surface, most notably matrix metalloproteinases, integrin-β1, and cyclophilins (92) . Thus, approaches that selectively target CD147-MCT interactions are likely needed to establish a therapeutic window.
The lactate shuttle
MCTs also facilitate the shuttling of lactate between cell populations under normal conditions, for example between astrocytes, which produce lactate and express MCT1 and MCT4, and neurons, which express MCT2 (93) . This shuttling of lactate, as opposed to a unidirectional export of the acid into the extracellular milieu, appears to play important roles in the development, growth, and metastasis of tumors. Indeed, three models of lactate shuttling have been described in cancer: the "reverse Warburg effect," metabolic symbiosis, and vascular endothelial cell shuttling. Notably, inhibiting MCT function in any of these situations contributes to the anticancer activity of MCT inhibitors in vivo.
The reverse Warburg effect proposes that tumor cells can provoke neighboring stromal cells to become glycolytic and export lactate (and ketones and perhaps pyruvate), which is then taken up by cancer cells and used for oxidative metabolism (94) . In this model, cancer cells are thought to create a "pseudo-hypoxic" environment for stromal fibroblasts by secreting hydrogen peroxide (95) , which activates HIF-1α, glycolysis, and MCT4 expression in stromal cells. The newly generated lactate is then exported from stromal cells via MCT4 and imported into cancer cells via MCT1 (Figure 3 ). In support of this model, analyses of breast cancer xenografts have shown that PKM2 and MCT4 are indeed expressed in stromal fibroblasts, while markers of mitochondrial mass (TOMM20), OXPHOS (COX), and MCT1 can be detected in breast cancer cells (96) (97) (98) . The induction of glycolysis in fibroblasts and lactate oxidation in cancer cells can be recapitulated in co-culture experiments, and the tumor cell-intrinsic roles of MCT1 in this shuttling have been demonstrated by MCT1 knockdown and by inhibition with CHC (99, 100). However, the reverse Warburg effect is certainly not a universal occurrence in tumors, because many tumor types are highly glycolytic and/or express MCT4. Nonetheless, it is easy to envision how this interplay could be manifest during tumor development, for example in scenarios where ATP production is more important than anabolic growth.
Lactate shuttling has also been suggested between cancer cells within a tumor, a form of metabolic symbiosis (101) . In this model, highly glycolytic, hypoxic tumor cells produce and efflux lactate, which is then imported and metabolized by more oxidative tumor cells. This shuttling is thought to facilitate glucose delivery from the vasculature into the tumor to supply hypoxic tumor cells (Figure 3 ). Sonveaux and colleagues have demonstrated that MCT1 expression and hypoxic regions of xenograft tumors are mutually exclusive (101) . Furthermore, the growth of xenograft tumors can be impaired by CHC (101) . These findings suggest that MCT1 can direct lactate uptake into tumor cells that rely on OXPHOS, and that MCT functions are critical for tumor growth. Moreover, CHC appears to effectively starve the more hypoxic regions of the tumor by forcing oxidative tumor cells to rely on glucose rather than lactate. In support of this model, CHC treatment can provoke a temporary redistribution of glucose uptake from strictly hypoxic to both hypoxic and nonhypoxic regions in tumor xenografts (102 following import via MCT1, lactate induces endothelial cell migration, tube formation, and tumor angiogenesis. Lactate-induced signaling in endothelial cells may stabilize HIF-1α and activate an autocrine NFB/IL-8 pathway (103, 104) (Figure 3) . Mechanistically, HIF-1α stabilization is thought to occur via the conversion of lactate to pyruvate, which competes with αKG for binding to prolylhydroxylases (PHDs), which normally hydroxylate proline residues in HIF-1α and mark them for ubiquitylation and destruction by the proteasome (105, 106) . In support of this model, knockdown or inhibition of MCT1 prevents lactate-mediated stabilization of HIF-1α ex vivo, and CHC inhibits angiogenesis in tumor xenografts (103, 104) . On the other hand, MCT1 was not detected on the surface of tumor-associated blood vessels for a large collection (over 500) of human tumors (107) . However, the ability of lactate to induce HIF-1α is not restricted to vascular endothelial cells and occurs in some tumor cell lines (105, 108) .
The promise of targeting lactate metabolism and transport
The new-found roles of lactate on so many components of tumor cell biology -from a tumor cell-intrinsic role as a key metabolic regulator to the interactions of cancer cells with neighboring cancer cells, stroma, and the vasculature -as well as the potent anticancer activity of LDHA and MCT inhibitors, validate this circuit as a high-priority target for next-generation cancer metabolism therapeutics. Top goals include the development of more potent and selective LDHA inhibitors, the identification and optimization of MCT4 inhibitors or pan-MCT inhibitors, and agents that target CD147 (e.g., small molecules and humanized anti-CD147 therapeutic antibodies). Of course, concerns regarding an appropriate therapeutic window will arise in the course of developing such agents given, for example, the high levels of MCTs that are expressed in muscle tissue. On the other hand, such agents appear safe, and top MCT1/MCT2 and LDHA inhibitors are in clinical oncology trials (Table 1) . Therefore, there is real hope that agents that target lactate metabolism and transport will add to our anticancer armament. Finally, to optimize the efficacy of such agents, a better understanding of lactate shuttling in human malignancies is clearly needed, including studies that address tumor type and the stages of tumor development at which shuttling occurs.
